Research ArticleNeuropharmacology
Open Access
Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer’s Disease—Studies on Relation to Effective Target Occupancy
Torsten Hoffmann, Antje Meyer, Ulrich Heiser, Stephan Kurat, Livia Böhme, Martin Kleinschmidt, Karl-Ulrich Bühring, Birgit Hutter-Paier, Martina Farcher, Hans-Ulrich Demuth, Inge Lues and Stephan Schilling
Journal of Pharmacology and Experimental Therapeutics July 2017, 362 (1) 119-130; DOI: https://doi.org/10.1124/jpet.117.240614
Torsten Hoffmann
Probiodrug AG, Halle, Germany (T.H., A.M., U.H., L.B., K.-U.B., I.L.); QPS Austria, Grambach, Austria (S.K., B.H.-P., M.F.); and Fraunhofer Institute for Cell Therapy and Immunology, Department for Drug Design and Target Validation, Halle, Germany (M.K., H.-U.D., S.S.)
Antje Meyer
Probiodrug AG, Halle, Germany (T.H., A.M., U.H., L.B., K.-U.B., I.L.); QPS Austria, Grambach, Austria (S.K., B.H.-P., M.F.); and Fraunhofer Institute for Cell Therapy and Immunology, Department for Drug Design and Target Validation, Halle, Germany (M.K., H.-U.D., S.S.)
Ulrich Heiser
Probiodrug AG, Halle, Germany (T.H., A.M., U.H., L.B., K.-U.B., I.L.); QPS Austria, Grambach, Austria (S.K., B.H.-P., M.F.); and Fraunhofer Institute for Cell Therapy and Immunology, Department for Drug Design and Target Validation, Halle, Germany (M.K., H.-U.D., S.S.)
Stephan Kurat
Probiodrug AG, Halle, Germany (T.H., A.M., U.H., L.B., K.-U.B., I.L.); QPS Austria, Grambach, Austria (S.K., B.H.-P., M.F.); and Fraunhofer Institute for Cell Therapy and Immunology, Department for Drug Design and Target Validation, Halle, Germany (M.K., H.-U.D., S.S.)
Livia Böhme
Probiodrug AG, Halle, Germany (T.H., A.M., U.H., L.B., K.-U.B., I.L.); QPS Austria, Grambach, Austria (S.K., B.H.-P., M.F.); and Fraunhofer Institute for Cell Therapy and Immunology, Department for Drug Design and Target Validation, Halle, Germany (M.K., H.-U.D., S.S.)
Martin Kleinschmidt
Probiodrug AG, Halle, Germany (T.H., A.M., U.H., L.B., K.-U.B., I.L.); QPS Austria, Grambach, Austria (S.K., B.H.-P., M.F.); and Fraunhofer Institute for Cell Therapy and Immunology, Department for Drug Design and Target Validation, Halle, Germany (M.K., H.-U.D., S.S.)
Karl-Ulrich Bühring
Probiodrug AG, Halle, Germany (T.H., A.M., U.H., L.B., K.-U.B., I.L.); QPS Austria, Grambach, Austria (S.K., B.H.-P., M.F.); and Fraunhofer Institute for Cell Therapy and Immunology, Department for Drug Design and Target Validation, Halle, Germany (M.K., H.-U.D., S.S.)
Birgit Hutter-Paier
Probiodrug AG, Halle, Germany (T.H., A.M., U.H., L.B., K.-U.B., I.L.); QPS Austria, Grambach, Austria (S.K., B.H.-P., M.F.); and Fraunhofer Institute for Cell Therapy and Immunology, Department for Drug Design and Target Validation, Halle, Germany (M.K., H.-U.D., S.S.)
Martina Farcher
Probiodrug AG, Halle, Germany (T.H., A.M., U.H., L.B., K.-U.B., I.L.); QPS Austria, Grambach, Austria (S.K., B.H.-P., M.F.); and Fraunhofer Institute for Cell Therapy and Immunology, Department for Drug Design and Target Validation, Halle, Germany (M.K., H.-U.D., S.S.)
Hans-Ulrich Demuth
Probiodrug AG, Halle, Germany (T.H., A.M., U.H., L.B., K.-U.B., I.L.); QPS Austria, Grambach, Austria (S.K., B.H.-P., M.F.); and Fraunhofer Institute for Cell Therapy and Immunology, Department for Drug Design and Target Validation, Halle, Germany (M.K., H.-U.D., S.S.)
Inge Lues
Probiodrug AG, Halle, Germany (T.H., A.M., U.H., L.B., K.-U.B., I.L.); QPS Austria, Grambach, Austria (S.K., B.H.-P., M.F.); and Fraunhofer Institute for Cell Therapy and Immunology, Department for Drug Design and Target Validation, Halle, Germany (M.K., H.-U.D., S.S.)
Stephan Schilling
Probiodrug AG, Halle, Germany (T.H., A.M., U.H., L.B., K.-U.B., I.L.); QPS Austria, Grambach, Austria (S.K., B.H.-P., M.F.); and Fraunhofer Institute for Cell Therapy and Immunology, Department for Drug Design and Target Validation, Halle, Germany (M.K., H.-U.D., S.S.)

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleNeuropharmacology
Pharmacological Profile of the QC Inhibitor PQ912
Torsten Hoffmann, Antje Meyer, Ulrich Heiser, Stephan Kurat, Livia Böhme, Martin Kleinschmidt, Karl-Ulrich Bühring, Birgit Hutter-Paier, Martina Farcher, Hans-Ulrich Demuth, Inge Lues and Stephan Schilling
Journal of Pharmacology and Experimental Therapeutics July 1, 2017, 362 (1) 119-130; DOI: https://doi.org/10.1124/jpet.117.240614
Research ArticleNeuropharmacology
Pharmacological Profile of the QC Inhibitor PQ912
Torsten Hoffmann, Antje Meyer, Ulrich Heiser, Stephan Kurat, Livia Böhme, Martin Kleinschmidt, Karl-Ulrich Bühring, Birgit Hutter-Paier, Martina Farcher, Hans-Ulrich Demuth, Inge Lues and Stephan Schilling
Journal of Pharmacology and Experimental Therapeutics July 1, 2017, 362 (1) 119-130; DOI: https://doi.org/10.1124/jpet.117.240614